A phase 1/2 trial of Dose Level 1, VNX-202 in advanced solid tumours, run by Vironexis Biotherapeutics Inc., now recruiting.
Gene Therapy for HER-Positive Cancer (SENTRY-HER2) is a phase 1/2 interventional study registered as NCT07192432 by Vironexis Biotherapeutics Inc., with 27 participants planned, started 2025-11-18 and due to reach its primary completion in 2033-09. Interventions recorded: Dose Level 1, VNX-202, Dose Level 2, VNX-202, Dose Level 3, VNX-202 and Dose Level 4, VNX-202.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Vironexis Biotherapeutics and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares HER2, Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.
Shares Metastatic cancer (cancer that has spread) and the tag pipeline.